Jounce Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare ConferenceHomeMailNewsFinanceSportsEntertainmentSearchMobileMore...YAHOO_FINANCESearchSign inMailSign in to view your mailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechU.S. Markets closedS&P 5002,978.76-137.63(-4.42%)Dow 3025,766.64-1,190.95(-4.42%)Nasdaq8,566.48-414.29(-4.61%)Jounce Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireJanuary 9, 2020ReblogShareTweetShareCAMBRIDGE, Mass., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Richard Murray, Ph.D., chief executive officer and president of Jounce Therapeutics, will present at the 38th Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2020 at 8:00 AM PT (11:00 AM ET) in San Francisco. Following the presentation, management will participate in a question and answer session at 8:30 AM PT (11:30 AM ET).A live webcast of the presentation will be available by visiting “Events and Presentations” in the Investors and Media section of Jounce’s website at www.jouncetx.com. A replay of the webcast will be archived for 30 days following the presentation.About Jounce TherapeuticsJounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within the human tumor microenvironment to prioritize targets, and then identifies related biomarkers designed to match the right immunotherapy to the right patient. Jounce is developing two clinical-stage programs, vopratelimab, a monoclonal antibody that binds to and activates ICOS, and JTX-4014, a PD-1 inhibitor intended for potential combination use with Jounce’s broader pipeline. Vopratelimab is currently being assessed in a Phase 2 clinical trial and JTX-4014 Phase 1 data were reported in November 2019 with additional studies planned. Jounce is also advancing and building out its broad and wholly-owned discovery pipeline of immuno-oncology targets, including those expressed on T-regulatory cells, macrophages and stromal cells. In addition, Jounce has exclusively licensed worldwide rights to JTX-8064, a LILRB2 receptor antagonist, to Celgene, a wholly owned subsidiary of Bristol-Myers Squibb Company. For more information, please visit www.jouncetx.com.Investor and Media Contact:Komal JoshiJounce Therapeutics, Inc.(857) 320-2523kjoshi@jouncetx.comReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextBiocontainment expert on coronavirus: There's no need for average people to panic yetYahoo FinanceA drug shortage due to the coronavirus is a 'considerable risk:' Fmr. FDA deputy commissionerYahoo Finance VideoStock market live updates: Dow drops 1190 points amid coronavirus fears, S&P 500 sees fastest correction in historyYahoo FinanceAmid coronavirus, bitcoin has fallen 6% this week to below $8,800Yahoo FinanceEl-Erian: The Fed will cut rates in March, if not beforeYahoo Finance Video'Stuck in no man’s land': A working mom details dealing with her sick child's student loan billYahoo FinanceDon’t buy the stock dip yet, says Goldman as it warns coronavirus will wipe out earnings growth this yearMarketWatchRichard Branson’s Wealth Falls to Earth as Virgin Galactic SputtersBloombergCoronavirus-induced stock selloff means IPO market is 'on holiday': veteran IPO analystYahoo FinanceMarket Watcher: Over six months we will see the markets higher Yahoo Finance VideoMost face masks won’t protect you from the coronavirusYahoo FinanceStock market live updates: Stock futures climb after historic rout; coronavirus fears persistYahoo FinanceWhat the GM strike means for the U.S. economyYahoo FinanceBeyond Meat beats on Q4 earnings, founder says 'we would be crazy not to invest in growth right now'Yahoo FinanceWhat to watch in the markets: Friday, February 28Yahoo Finance VideoAurora Cannabis tumbles after double downgradeYahoo Finance Video